FDA approves first treatment option specifically for patients with epithelioid sarcoma
- Details
- Category: FDA
Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ).
FDA approves first treatment for thyroid eye disease
- Details
- Category: FDA
Today, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). Today's approval represents the first drug approved for the treatment of thyroid eye disease.
FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
- Details
- Category: FDA
The U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST) - a type of tumor that occurs in the gastrointestinal tract,
FDA approves new treatment for adults with migraine
- Details
- Category: FDA
The U.S. Food and Drug Administration approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Ubrelvy is not indicated for the preventive treatment of migraine.
FDA approves first generics of Eliquis
- Details
- Category: FDA
The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Apixaban is also indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
- Details
- Category: FDA
Today, the U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
FDA approves new type of therapy to treat advanced urothelial cancer
- Details
- Category: FDA
The U.S. Food and Drug Administration granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells - in this case, the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers.
More Pharma News ...
- FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation
- FDA launches app for health care professionals
- FDA approves first generics of Gilenya
- FDA approves novel treatment to target abnormality in sickle cell disease
- FDA approves first treatment for inherited rare disease
- FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
- FDA approves first therapy to treat patients with rare blood disorder